Chicago, IL – June 2, 2026 – The American Society of Clinical Oncology (ASCO) annual meeting, a premier global forum for cancer research, has once again served as a pivotal stage for groundbreaking advancements in the treatment of multiple myeloma. This year’s congress saw two pharmaceutical giants, Bristol Myers Squibb (BMS) and Johnson & Johnson (J&J), present compelling positive data for their respective novel therapies, signaling a new era of improved outcomes and expanded treatment options for patients battling this complex blood cancer. The findings underscore a significant leap forward in managing relapsed and refractory multiple myeloma (RRMM), with both companies demonstrating substantial gains in progression-free survival (PFS), overall response rates (ORR), and the potential to shift treatment paradigms towards earlier intervention and outpatient settings.
A Year of Promising Progress: Key Findings Emerge at ASCO 2026
The 2026 ASCO meeting buzzed with anticipation as data from several pivotal multiple myeloma studies were unveiled. Beyond the headline-grabbing results from BMS and J&J, an investigator-led study also highlighted the feasibility and efficacy of administering promising myeloma therapies in an outpatient setting, further enhancing patient convenience and potentially reducing healthcare burdens. These collective presentations paint a picture of a field in rapid evolution, driven by innovative science and a commitment to addressing unmet patient needs.
BMS’s Mezigdomide Combination Achieves Remarkable 18-Month Progression-Free Survival in RRMM
Bristol Myers Squibb (BMS) presented highly encouraging data from the Phase III SUCCESSOR-2 trial (NCT05572515), showcasing the significant impact of its novel cereblon E3 ligase modulator, mezigdomide, when used in combination with carfilzomib and dexamethasone (collectively termed MeziKd). The trial, which enrolled patients with relapsed or refractory multiple myeloma (RRMM), demonstrated a remarkable median progression-free survival (PFS) of 18 months for patients treated with MeziKd. This represents a substantial improvement compared to the 8.3 months of PFS observed in patients receiving carfilzomib and dexamethasone (Kd) alone.
The MeziKd regimen achieved a 52% reduction in the risk of disease progression or death, a statistically significant and clinically meaningful outcome for patients with limited treatment options. Further analysis revealed that the benefits of MeziKd were consistent across various patient subgroups, including those in their second and third lines of therapy, as well as individuals with higher-risk disease. This broad efficacy suggests that MeziKd could become a valuable therapeutic option for a wide spectrum of RRMM patients.
Beyond PFS, the MeziKd combination also significantly outperformed the Kd regimen in terms of response rates. The overall response rate (ORR) was an impressive 80.2% with MeziKd, compared to 53.4% with Kd. Furthermore, the complete response (CR) or better rate was substantially higher with MeziKd at 26.7%, versus 8.9% for Kd. While the median overall survival had not yet been reached at the time of data cutoff, these robust response rates are highly indicative of long-term patient benefit.
Safety Profile and Expert Commentary:
The safety profile of MeziKd was reported as consistent with the known safety of mezigdomide and the combination regimen. Grade 3-4 treatment-emergent adverse events (TEAEs) were observed in 83.7% of patients receiving MeziKd, compared to 56.5% with Kd. Notably, neutropenia was reported in 61.1% of MeziKd-treated patients versus 9.1% with Kd, and infections occurred in 34.0% of the MeziKd arm compared to 15.6% in the Kd arm. These safety findings, while requiring careful monitoring, are considered manageable within the context of advanced myeloma treatment.
Dr. Paul Richardson, Director of Clinical Research and Clinical Program Leader at the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, emphasized the significance of these findings. "Maintaining durable disease control becomes an increasing challenge with each line of therapy for patients with relapsed or refractory disease and increasing resistance to therapy," Dr. Richardson stated. "So, achieving extended progression-free survival of a year and a half is especially meaningful. These promising results at ASCO underscore MeziKd’s potential, particularly for those patients who need additional options after both early and later relapse."
BMS has indicated its intention to present these pivotal data to regulatory authorities, paving the way for potential approval and broader patient access to this promising new treatment.
J&J’s Tecvayli Poised for Earlier Intervention in Multiple Myeloma Treatment Landscape
Johnson & Johnson (J&J) also presented impactful data at ASCO 2026, focusing on its bispecific T-cell engager, Tecvayli (teclistamab-cqyv). Findings from the Phase III MajesTEC-9 study (NCT05572515) suggest that Tecvayli could play a crucial role in earlier lines of therapy for patients with RRMM, potentially revolutionizing the treatment paradigm.
The MajesTEC-9 study investigated Tecvayli as a treatment option as early as the second line of therapy for patients with RRMM. In this setting, Tecvayli demonstrated a significant reduction in the risk of disease progression or death by 71% and a 40% reduction in the risk of death when compared to standard-of-care (SoC) regimens, which included pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd).
All key secondary endpoints in the study showed significant improvements with Tecvayli compared to SoC. Notably, nearly two-thirds of patients treated with Tecvayli achieved a complete response (CR) or better, highlighting the drug’s potent anti-myeloma activity.
Safety and Outpatient Potential:
The safety profile of Tecvayli was found to be comparable to the SoC regimens, with similar rates of TEAEs (99.7% for Tecvayli vs. 97.9% for SoC). Grade 3-4 TEAEs were reported in 84.9% of patients treated with Tecvayli, compared to 76.3% of patients receiving SoC. These findings indicate that while side effects are common, they are generally manageable and comparable to existing treatments.
Dr. Roberto Mina, Associate Professor at the Winship Cancer Institute of Emory University, commented on the implications of the MajesTEC-9 data. "These findings further reinforce Tecvayli’s potential to meaningfully improve survival outcomes for patients with multiple myeloma in earlier lines," Dr. Mina stated. "These results will continue to transform the role of bispecifics in clinical decision-making as early as first relapse – offering a steroid-sparing, community-based therapy for patients across all practice settings, regardless of prior anti-CD38 exposure."
Based on this compelling evidence, J&J is actively engaging with regulatory bodies worldwide to explore the potential for Tecvayli to be utilized as early as the second line of treatment for RRMM. This strategic move could significantly expand the reach and impact of this innovative therapy.
Investigator-Led Study Explores Outpatient Administration of Bispecifics
Complementing the pharmaceutical-sponsored trials, an investigator-led Phase II study, conducted by the Sarah Cannon Research Institute (SCRI), explored the feasibility and efficacy of administering bispecific antibodies, specifically Tecvayli and Talvey (talquetamab), in an outpatient setting for patients with RRMM. This study, (NCT05972135), also incorporated a step-up dosing strategy with prophylactic Actemra (tocilizumab) to manage potential cytokine release syndrome (CRS).
Dr. Peter Forsberg of the SCRI at Colorado Blood Cancer Institute presented the data at ASCO. The study revealed promising response rates in both treatment arms. In the Tecvayli cohort, the ORR was 68.9%, with a stringent complete response (sCR) rate of 6.7% and a CR rate of 17.8%. In the Talvey cohort, the ORR was 71.4%, with an sCR rate of 14.3% and a CR rate of 14.3%. Very good partial response (VGPR) was observed in 26.7% of the Tecvayli arm and 42.9% of the Talvey arm.
After a median follow-up of 11.8 months for patients treated with Tecvayli, 75.6% remained free from disease progression. While some patients discontinued treatment due to progression, adverse events, or physician recommendation, the ability to administer these potent therapies in an outpatient setting offers significant advantages in terms of patient convenience and potentially reduced healthcare costs. Notably, no progression events were reported in the Talvey arm at the time of data presentation.
This investigator-initiated research highlights the evolving landscape of myeloma treatment, where accessibility and patient-centric care are becoming increasingly important considerations. The successful implementation of bispecific antibody therapy in an outpatient setting could pave the way for wider adoption and improved quality of life for patients.
Implications for the Future of Multiple Myeloma Treatment
The data presented at ASCO 2026 by BMS and J&J, along with the insights from the investigator-led study, collectively signal a transformative period for multiple myeloma management.
-
Enhanced Efficacy: The significant improvements in PFS and ORR demonstrated by MeziKd and Tecvayli offer new hope for patients with relapsed and refractory disease, many of whom face limited treatment options and a high risk of progression. The extended PFS achieved by MeziKd is particularly noteworthy, suggesting the potential for longer periods of disease control.
-
Earlier Intervention: The potential for Tecvayli to be used as early as the second line of therapy could fundamentally alter the treatment trajectory for many patients. Initiating highly effective therapies earlier in the disease course can lead to deeper responses and potentially improve long-term outcomes.
-
Outpatient Accessibility: The exploration of outpatient administration for bispecific antibodies like Tecvayli and Talvey addresses a critical need for more convenient and patient-friendly treatment options. This shift could reduce the burden of hospital visits and improve the overall patient experience.
-
Diversification of Therapeutic Strategies: The continued development and success of novel mechanisms of action, such as cereblon E3 ligase modulation and bispecific T-cell engagers, underscore the increasing diversity of therapeutic strategies available for multiple myeloma. This diversification is crucial for overcoming treatment resistance and addressing the heterogeneity of the disease.
As regulatory bodies review the promising data for MeziKd and Tecvayli, and as outpatient administration protocols are further refined, the landscape of multiple myeloma treatment is poised for significant and positive evolution. The 2026 ASCO meeting has undoubtedly set a new benchmark for what can be achieved in the fight against this challenging cancer.
About the Author
